Dear Dr. Tammara:


We acknowledge receipt of your submissions dated May 16, July 19, July 20, November 17, and December 7, 2005, and January 10, 13, February 8, and March 6 (email), 10, 2006.

Supplement-006 provides for changes to the CLINICAL STUDIES, Primary Hypercholesterolemia, Vytorin subsection of the package insert to add efficacy data for the ezetimibe/simvastatin combination product and for an atorvastatin product on LDL-C and other lipid parameters in patients with hypercholesterolemia.

Supplement-013 provides for the addition of “anaphylaxis” to the ADVERSE REACTIONS section, Ezetimibe, Post-marketing Experience subsection of the Vytorin package insert.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted draft labeling [package insert submitted March 6 (email), 2006](copy enclosed).

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions "FPL for approved supplement NDA 21-687/S-006, S-013." Approval of these submissions by FDA is not required before the labeling is used.
In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
Food and Drug Administration  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
WO 22, Room 4447  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301) 796-1295.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.  
Acting Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Eric Colman
3/16/2006 07:25:08 PM
Acting Deputy Division Director